YEAR
- 2013.03.27 Structural basis for the drug extrusion mechanism by a MATE multidrug transporter. Tanaka Y, Hipolito CJ, Maturana AD, Ito K, Kuroda T, Higuchi T, Katoh T, Kato HE, Hattori M, Kumazaki K, Tsukazaki T, Ishitani R, Suga H, Nureki O.Nature. 2013 Apr 11;496(7444):247-51. doi: 10.1038/nature12014
- 2013.06.24 Structural basis for dynamic mechanism of proton-coupled symport by the peptide transporter POT. Doki S, Kato HE, Solcan N, Iwaki M, Koyama M, Hattori M, Iwase N, Tsukazaki T, Sugita Y, Kandori H, Newstead S, Ishitani R, Nureki O.Proc. Natl. Acad. Sci. U.S.A. 2013 Jul 09;110(28):11343-8. doi: 10.1073/pnas.1301079110
- 2013.01.29 Structural and Spectral Characterization of C1C2 Channelrhodopsin and its Mutants by Molecular Simulations Kamiya, M., Kato, H.E., Ishitani, R., Nureki, O., Hayashi, S.Chem. Phys. Lett. 556, 266-71 (2013). https://doi.org/10.1016/j.cplett.2012.11.066
- 2013.04.17 Sperm-associated antigen 4, a novel hypoxia-inducible factor 1 target, regulates cytokinesis, and its expression correlates with the prognosis of renal cell carcinoma. Shoji K, Murayama T, Mimura I, Wada T, Kume H, Goto A, Ohse T, Tanaka T, Inagi R, van der Hoorn FA, Manabe I, Homma Y, Fukayama M, Sakurai T, Hasegawa T, Aburatani H, Kodama T, Nangaku M.Am. J. Pathol. 2013 Jun;182(6):2191-203. doi: 10.1016/j.ajpath.2013.02.024
- 2013.03.20 Screening of liver-targeted drugs. Midorikawa Y, Sugiyama Y, Aburatani H.Expert Opin Drug Discov. 2008 Jun;3(6):643-54. doi: 10.1517/17460441.3.6.643
- 2013.08.28 Revolution of nephrology research by deep sequencing: ChIP-seq and RNA-seq. Mimura I, Kanki Y, Kodama T, Nangaku M.Kidney Int. 2014 Jan;85(1):31-8. doi: 10.1038/ki.2013.321
- 2013.08.18 Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Kon A, Shih LY, Minamino M, Sanada M, Shiraishi Y, Nagata Y, Yoshida K, Okuno Y, Bando M, Nakato R, Ishikawa S, Sato-Otsubo A, Nagae G, Nishimoto A, Haferlach C, Nowak D, Sato Y, Alpermann T, Nagasaki M, Shimamura T, Tanaka H, Chiba K, Yamamoto R, Yamaguchi T, Otsu M, Obara N, Sakata-Yanagimoto M, Nakamaki T, Ishiyama K, Nolte F, Hofmann WK, Miyawaki S, Chiba S, Mori H, Nakauchi H, Koeffler HP, Aburatani H, Haferlach T, Shirahige K, Miyano S, Ogawa S.Nat. Genet. 2013 Oct;45(10):1232-7. doi: 10.1038/ng.2731
- 2013.12.30 Primary tumours modulate innate immune signalling to create pre-metastatic vascular hyperpermeability foci. Hiratsuka S, Ishibashi S, Tomita T, Watanabe A, Akashi-Takamura S, Murakami M, Kijima H, Miyake K, Aburatani H, Maru Y.Nat Commun. 2013;4:1853. doi: 10.1038/ncomms2856
CLOSE